CMS proposes Medicare payment rules for SNFs, 3 others
CMS has proposed Medicare payment updates for four provider types, including skilled nursing facilities (SNFs), hospices, inpatient rehabilitation facilities (IRFs), and inpatient psychiatric facilities (IPFs). These facilities are expected to see payment increases of over 2% in fiscal year 2027, alongside updates to quality reporting programs. Additionally, CMS aims to enhance oversight of hospices to combat fraud, waste, and abuse, introducing new transparency measures and stronger monitoring.
IVF In Animals Market Generated Opportunities, Future Scope
Coherent Market Insights has published a report titled "IVF In Animals Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report details market competition, geographic distribution, growth potential, industry performance, and key success factors. Leading players include Zoetis, Merck Animal Health, and Elanco Animal Health, with segmentation covering various animal types.
Labcorp (NYSE:LH) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen downgraded Labcorp (NYSE:LH) from "buy" to "hold," though the broader analyst consensus remains a "Moderate Buy" with a target price of $307.70. Labcorp beat its quarterly EPS expectations but slightly missed revenue estimates, and its insiders have engaged in modest stock selling. The company, a global life sciences firm, provides extensive clinical laboratory and drug development services.
Nearly 300 N.J. healthcare layoffs: Novartis, Labcorp among companies cutting jobs
Nearly 300 healthcare jobs in New Jersey are slated for elimination this year by companies including Novartis Pharmaceuticals, Labcorp, and Reckitt Benckiser. Novartis plans to cut 114 jobs as part of a restructuring effort, while Labcorp will eliminate 83 positions. Reckitt Benckiser and its subsidiaries are also cutting nearly 100 jobs combined.
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles
NeoGenomics Inc. specializes in precision oncology diagnostics, holding a critical niche in cancer genetics testing with laboratories across the U.S. While the company operates in a high-growth sector and strategically serves both clinical oncology and pharmaceutical drug development, it faces significant profitability hurdles with ongoing net losses due to heavy investments. North American investors are advised to monitor its progress toward profitability and navigate the competitive diagnostics market before making investment decisions.
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles
NeoGenomics Inc. specializes in precision oncology diagnostics, offering cancer genetics testing and pharmaceutical services, primarily in the U.S. While the company operates in a high-growth sector driven by rising cancer rates and advancing therapies, it faces profitability hurdles with persistent net losses due to heavy investments. Investors are advised to watch their growth trajectory, market share gains in precision oncology, and the path to profitability, balancing growth prospects against execution risks and competitive pressures.
Aberdeen Group plc Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Aberdeen Group plc increased its stake in Thermo Fisher Scientific Inc. by 1.6% in the fourth quarter, bringing its total ownership to 383,832 shares valued at $222.4 million. Other institutional investors also adjusted their positions, and analysts generally maintain a "Moderate Buy" rating for TMO, with a consensus target price of $632.50. The company recently reported strong quarterly earnings, exceeding analyst expectations, and increased its quarterly dividend.
HSBC Adjusts Price Target on Labcorp Holdings to $270 From $260, Maintains Hold Rating
HSBC has increased its price target for Labcorp Holdings (NYSE: LH) shares to $270, up from the previous $260. The firm has, however, decided to maintain its "Hold" rating on the company's stock. This adjustment suggests a modest increase in the expected valuation of Labcorp Holdings by HSBC.
Illumina Announces Changes to Board of Directors
Illumina, Inc. announced changes to its Board of Directors. Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board, and David P. King has been nominated to be elected as a new member. David P. King brings extensive experience in healthcare and life sciences, having served in executive roles at Laboratory Corporation of America Holdings and currently holding directorships at Privia Health, AmSurg Corporation, and Smith & Nephew.
In 211 myeloma samples, OGM found abnormalities older tests missed
Bionano (Nasdaq: BNGO) announced a multicenter study published in April 2026, demonstrating that optical genome mapping (OGM) outperforms traditional cytogenetic methods in analyzing multiple myeloma (MM) samples. The study, involving 211 MM samples, found that OGM identified relevant abnormalities in 92% of cases previously deemed normal by karyotype and resolved 82% of samples that failed karyotyping, also detecting complex events like chromoanagenesis in ~29% of samples. This suggests OGM can provide a more comprehensive view of genomic alterations and addresses medical society recommendations for MM analysis, potentially driving increased adoption and utilization of OGM.
Exosomes Market Evolution (2026) | Nano Vesicles, Liquid Biopsy, Oncology Research & Biotech Investments | Top Companies 2026 - Miltenyi Biotec, Novus Biologicals, Capital Biosciences, and Bio Techne
DataM Intelligence has released a new research report on the Exosomes Market, highlighting its projected growth between 2026 and 2033. The report offers in-depth insights into market dynamics, segmentation, and includes recent industry developments and mergers & acquisitions. Key players listed include Thermo Fisher Scientific Inc., Qiagen, Beckman Coulter, Inc., and Lonza, among others, with the market focusing on oncology, neurodegenerative diseases, and regenerative medicine applications.
Exosome Research Market is Thriving Worldwide | Thermo Fisher Scientific, Illumina Inc, Miltenyi Biotec, QIAGEN
The Exosome Research Market is projected to grow from USD 284.5 million in 2026 to USD 895.5 million by 2033, exhibiting a compound annual growth rate of 17.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report, by Coherent Market Insights, provides a detailed analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.
Labcorp Sets Date for First-Quarter 2026 Results
Labcorp (LH) announced it will release its first-quarter 2026 financial results on Thursday, April 30, 2026, before the U.S. market opens, followed by a webcast. The company, a major global laboratory services provider, emphasizes transparency and investor engagement. Analysts currently rate LH stock as a "Hold" with a $280.00 price target.
Labcorp to offer Roche, Lilly Alzheimer's blood test starting in early 2026
Labcorp announced it will begin offering the Roche / Eli Lilly Alzheimer's blood test in early 2026. This test aims to help identify patients with Alzheimer's disease. The collaboration expands access to an important diagnostic tool for the neurodegenerative condition.
Labcorp Holdings Inc. stock outperforms competitors on strong trading day
Shares of Labcorp Holdings Inc. (LH) rose 2.22% to $272.74 on Wednesday, outperforming the broader market which also saw gains. The S&P 500 Index and the Dow Jones Industrial Average both closed higher. This marks the second consecutive day of gains for Labcorp's stock.
Illumina (ILMN) Valuation Check As Labcorp Partnership Expands In Precision Oncology
Illumina has expanded its collaboration with Labcorp, focusing on next-generation sequencing in precision oncology. Despite recent share price declines, the company trades at a 19% intrinsic discount and 13% below analyst targets. The article details Illumina's valuation, which suggests it is 11.2% undervalued based on a narrative highlighting strong growth in clinical applications and increasing adoption of genomic technologies.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp (NYSE: LH) will release its first-quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET to discuss the results, with the earnings press release and webcast details available on its investor relations website. Labcorp is a global leader in laboratory services, providing diagnostics and drug development capabilities to clients in approximately 100 countries.
Competitive Analysis: Key Market Leaders and New Entrants in the Lyme Disease Testing Industry
The Lyme disease testing market is projected to reach $16.46 billion by 2030, growing at a CAGR of 9.0%, driven by advancements in diagnostics and increased awareness of tick-borne illnesses. Key trends include AI-assisted tools, home-testing kits, and multi-disease panels. Companies like Roche, Thermo Fisher Scientific, and Quest Diagnostics are leading innovation, with strategic partnerships and technological advancements enhancing early and precise detection methods.
Global Biostorage Service Market Size is Expected to Reach USD 655.81 Million by 2026
The global Biostorage Service market is projected to reach $1,658.22 million by 2033, growing from $655.81 million in 2026 with a CAGR of 14.17%. This growth is driven by advancements in precision medicine, biopharmaceutical R&D, and the expansion of new drug development. Key market players include Azenta, Thermo Fisher Scientific, and EPL Archives (VWR), with North America being the largest market.
VivoSim Announces Pricing of up to a $4 Million Public Offering
VivoSim Labs, Inc. announced the pricing of a best-efforts public offering aiming to raise up to $4 million. An initial closing of $3 million is expected, involving the sale of common stock and pre-funded warrants, along with common warrants. A second closing for an additional $1 million is conditioned on certain market factors.
Assenagon Asset Management S.A. Sells 32,625 Shares of Labcorp Holdings Inc. $LH
Assenagon Asset Management S.A. significantly reduced its stake in Labcorp Holdings Inc. by selling 32,625 shares, retaining only 3,587 shares valued at $900,000. Despite this institutional sell-off, Labcorp reported stronger-than-expected EPS and announced a quarterly dividend of $0.72 per share. Analyst sentiment remains "Moderate Buy" with a consensus price target of $304.82, even as company insiders sold a considerable number of shares.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp (NYSE: LH) will release its first-quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss these results. The financial information and webcast link will be available on the Labcorp Investor Relations website.
Should Labcorp’s Expanded Illumina Oncology Partnership Reshape the Precision Medicine Story for LH Investors?
Labcorp and Illumina have expanded their precision oncology partnership to enhance access to next-generation sequencing-based cancer tests, including co-commercializing both tissue and liquid biopsy options. This collaboration aims to support drugmakers and strengthen payer coverage for comprehensive genomic profiling. While the partnership reinforces Labcorp's oncology testing franchise, investors are cautioned that it may not significantly alter short-term financial sensitivities to reimbursement shifts or broader economic headwinds.
Should Labcorp’s Expanded Illumina Oncology Partnership Reshape the Precision Medicine Story for LH Investors?
Labcorp and Illumina have expanded their oncology collaboration to develop and co-commercialize next-generation sequencing-based cancer tests, including Labcorp's PGDx elio plasma focus Dx liquid biopsy and Illumina's TruSight Oncology Comprehensive. This partnership aims to increase access to biomarker testing and support drugmakers, potentially enhancing Labcorp's oncology testing franchise. Investors should consider how this collaboration fits into Labcorp's investment narrative, alongside its 2026 revenue guidance and ongoing efforts in high-value genomic testing.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp (NYSE: LH) will release its first-quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss these results. The earnings press release and financial information will be available on Labcorp's Investor Relations website.
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
Onconetix, Inc. (Nasdaq: ONCO) has announced the appointment of David White as CEO and Sammy Dorf to its Board of Directors and Audit Committee. These strategic appointments are made as the company prepares for its transformative acquisition of Realbotix LLC, an AI-powered humanoid robot developer. The new leadership aims to leverage their extensive experience to drive the acquisition through and position the combined entity for long-term growth and shareholder value.
Labcorp Sets Date for First-Quarter 2026 Results
Labcorp (LH) announced it will release its first-quarter 2026 financial results on April 30, 2026, before market open, followed by a webcast at 9:00 a.m. ET. The company will provide detailed financial materials on its investor relations website. This announcement highlights Labcorp's commitment to transparent communication regarding its performance, especially concerning diagnostics demand and drug development trends, for which investors and industry stakeholders will be scrutinizing the upcoming results.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp (NYSE: LH) will release its first-quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss these results. The earnings press release and related financial information will be available on the "News & Events" section of the Labcorp Investor Relations website.
Labcorp Will Eliminate 83 Positions at Raritan Location in July
Labcorp is set to eliminate 83 jobs at its Raritan, New Jersey site on July 17, as confirmed by a WARN notice. The specific reasons for these cuts and which positions will be affected have not been disclosed by the life sciences firm. These layoffs contribute to a trend of job reductions in the healthcare and diagnostics sectors, potentially impacting Somerset County's economy and prompting local workforce development groups to offer support to affected employees.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp Holdings Inc. will release its first quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss the results, which will also be available on their investor relations website. Labcorp is a global leader in laboratory services, providing diagnostics and drug development capabilities worldwide.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp Holdings Inc. (NYSE: LH) will release its first quarter 2026 financial results on April 30, 2026, before market open. The company will host a webcast at 9:00 a.m. ET on the same day to discuss the results, with the earnings press release and webcast link available on its investor relations website. Labcorp is a global leader in laboratory services, providing diagnostics and drug development support to clients in approximately 100 countries.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp (NYSE: LH) will release its first-quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss these results. Financial information and webcast details will be available on the Labcorp Investor Relations website.
Veterinary Diagnostic Imaging Market Report 2026: Siemens Healthineers, General Electric, and Fujifilm Lead the $2.55 Billion Industry
The veterinary diagnostic imaging market is experiencing robust growth, projected to expand from $2.37 billion in 2025 to $2.55 billion in 2026, and is expected to reach $3.39 billion by 2030. Key drivers include increased pet ownership, demand for advanced veterinary care, and technological advancements like AI-assisted imaging and cloud-based systems. Major players such as Siemens Healthineers, General Electric, and Fujifilm are leading this growth, with significant activity in North America and anticipated rapid growth in Asia-Pacific.
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Labcorp Holdings Inc. (NYSE: LH) will release its first-quarter 2026 financial results before the market opens on Thursday, April 30, 2026. The company will host a webcast at 9:00 a.m. ET on the same day to discuss these results. The earnings press release and financial information will be available on the Labcorp Investor Relations website.
Labcorp will post first-quarter results before markets open April 30
Labcorp (NYSE: LH) is scheduled to report its first-quarter 2026 financial results before the market opens on April 30, 2026. The company will also host a live webcast at 9:00 a.m. ET on the same day to discuss the results. The earnings release and financial information will be made available on Labcorp's investor relations website, with a replay of the webcast accessible for one year.
Labcorp Holdings Inc. stock rises Tuesday, still underperforms market
Shares of Labcorp Holdings Inc. (LH) rose 1.21% on Tuesday to $266.81, breaking a two-day losing streak. Despite this gain, the stock underperformed the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average both rise significantly. The positive trading session for the market saw the S&P 500 increase by 2.91% and the Dow Jones Industrial Average by 2.49%.
Labcorp (NYSE: LH) EVP granted performance stock; shares withheld for tax
Labcorp EVP Mark S. Schroeder received performance-based stock awards and had shares withheld to cover tax obligations. He acquired 9,304 shares and 2,968 shares from performance awards granted in 2023, tied to the company's performance through 2025. A total of 6,068 shares were withheld at $268.38 per share for tax purposes, resulting in Schroeder directly holding 12,677.1426 shares of Labcorp common stock after these transactions.
Allspring Global Investments Holdings LLC Boosts Stake in Labcorp Holdings Inc. $LH
Allspring Global Investments Holdings LLC increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 10.4% in the fourth quarter of 2025, bringing its total holdings to 2,204,276 shares valued at $554.7 million. This makes Labcorp Allspring's ninth-largest holding, representing 0.9% of its portfolio. Various other institutional investors also adjusted their positions in Labcorp, while company insiders, including CEO Adam Schechter, recently sold shares.
Labcorp EVP Meltzer sells $224k in shares
Labcorp Executive Vice President, Operations, Jonathan C. Meltzer, sold 839 shares of company stock for over $224,000 on March 27, 2026. This transaction followed an acquisition of 2,388 shares from a performance award and the withholding of 711 shares for tax obligations. Meltzer now directly owns 3,620.3256 shares of Labcorp Holdings Inc.
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands
NeoGenomics Inc (NASDAQ: NEO) plays a crucial role in the cancer diagnostics sector by providing specialized oncology testing services essential for precision medicine. The company focuses on innovation in next-generation sequencing and companion diagnostics, positioning itself competitively against larger labs through specialization and proprietary assays. Investors can find long-term growth potential in NeoGenomics due to its alignment with rising cancer incidence rates and its service-oriented model delivering steady cash flows in the robust healthcare growth sector.
Labcorp (LH) EVP granted 6,604 shares; 2,879 withheld for tax
Anita Z. Graham, EVP and CHRO of Labcorp (LH), received a performance-based equity award of 6,604 shares on March 26, 2026. This award covered a three-year performance period ending December 31, 2025. To manage tax obligations, 2,879 shares were withheld at $268.38 per share, which is a common procedure and not an open-market sale. After these transactions, Graham directly holds 5,185 shares of Labcorp common stock.
Labcorp (NYSE: LH) CEO receives 58,470-share award, 26,106 withheld for taxes
Labcorp (NYSE: LH) President & CEO Adam H. Schechter was granted 58,470 shares of Common Stock as a performance award on March 26, 2026, stemming from the company's performance for the three-year period ending December 31, 2025. To cover the associated tax obligations, 26,106 shares were withheld at a price of $268.38 per share. Following these transactions, Schechter directly holds 113,137 shares of Labcorp Common Stock.
Labcorp (NYSE: LH) SVP sells shares after award under Rule 10b5-1
Labcorp (NYSE: LH) Senior Vice President and Chief Accounting Officer Peter J. Wilkinson reported transactions involving equity compensation. He acquired 2,388 common shares from a performance award, had 755 shares withheld for tax obligations, and then sold 1,633 shares under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Wilkinson directly holds 1,852.2194 shares of Labcorp common stock.
Emerging Sub-Segments Transforming the Drug Screening Market Landscape
The drug screening market is projected to reach $19.2 billion by 2030, growing at a CAGR of 14.5%, driven by technological advancements, regulatory demands, and innovations like AI-powered analytics and portable devices. Key growth areas include rapid testing kits, automated laboratory systems, digital reporting, and point-of-care testing. Strategic acquisitions and collaborations, such as Premier Biotech's acquisition of Desert Tox and Neopharma Technologies' partnership with Impairment Science, are further shaping the industry by expanding testing capacities and integrating advanced assessment tools.
A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Swings
Quest Diagnostics (DGX) has experienced recent stock volatility, dropping 8% over the past month, but maintaining positive returns over three months and a year. The company's current stock price of $195.51 is considered undervalued compared to a fair value estimate of $218.50, driven by analyst expectations of future earnings growth and profit margins. Investors are encouraged to consider the potential upsides while also being aware of risks like reimbursement cuts and rising operational costs.
Labcorp EVP Meltzer sells $224k in shares By Investing.com
Jonathan C. Meltzer, EVP of Operations at Labcorp (NYSE:LH), sold 839 shares of common stock for $224,054 on March 27, 2026, while also acquiring 2,388 shares related to a performance award. The company recently exceeded Q4 2025 EPS estimates and announced an expanded collaboration with PathAI for its digital pathology platform. Labcorp's stock has returned 16% over the past year, with analysts projecting a 12% upside.
Labcorp (LH) EVP gets 1,584-share award, 451 withheld for taxes
Labcorp's EVP of Diagnostics, Bryan T. Vaughn, received a performance award of 1,584 shares of common stock on March 26, 2026, tied to results from a three-year period ending December 31, 2025. To cover tax obligations, 451 shares were withheld, leaving him with 6,745.5702 directly owned shares. This transaction is noted as a routine compensation and tax-settlement entry rather than an open-market purchase or sale.
Labcorp EVP Meltzer sells $224k in shares
Labcorp Executive Vice President, Operations, Jonathan C. Meltzer, sold 839 shares of company stock for $224,054 on March 27, 2026. Prior to this, on March 26, 2026, Meltzer acquired 2,388 shares through a performance award and had 711 shares withheld for tax obligations. Following these transactions, Meltzer directly owns 3,620.3256 shares of Labcorp Holdings Inc., with the stock showing a 16% return over the past year and analysts projecting a 12% upside.
Labcorp (LH) CLO awarded 1,584 shares; 451 withheld for tax
Labcorp's EVP and Chief Legal Officer, Kathryn W. Kyle, was granted 1,584 shares of common stock as a performance award. To cover tax obligations, 451 shares were withheld at a value of $268.38 per share. Following these transactions, Kyle directly holds 4,575.4574 shares of Labcorp common stock.
Labcorp (LH) EVP Bailey granted 1,184 shares, 481 withheld for taxes
Labcorp EVP Megan D. Bailey was granted 1,184 shares of common stock as part of a performance award for the period ending December 31, 2025. To cover tax obligations, 481 shares were withheld at a price of $268.38 per share. Following these transactions, Bailey directly holds 4,851 shares of Labcorp common stock.
